Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.00% | -0.24% | +1.66% | +1.35% | +4.83% |
| Weighted Average Shares Diluted Growth | +0.00% | -0.24% | +1.66% | +1.35% | +4.83% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | -100.00% | +0.00% | -100.00% | +0.00% |
| Inventory Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -80.41% | -72.26% | -85.98% | -60.53% | +610.39% |
| Book Value per Share Growth | -79.70% | -81.25% | +0.00% | -69.71% | +1406.02% |
| Debt Growth | -93.02% | -7.49% | +1082.38% | +0.00% | -100.00% |
| R&D Expense Growth | +138.97% | +32.04% | -58.09% | -92.80% | +21.05% |
| SG&A Expenses Growth | +677.73% | +201.35% | +149.59% | +471.46% | -92.81% |